Sam Brusco, Associate Editor10.11.22
Beckman Coulter Diagnostics has acquired StoCastic, an artificial intelligence (AI) company that offers evidence-based decision support for hospital emergency departments.
StoCastic’s TriageGo toll will become a cornerstone of Beckman Coulter’s AI-enabled Clinical Decision Support (CDS) portfolio, which aims to improve patient care through data-driven insights for clinicians and boost decision making.
"Bringing in StoCastic innovations and talent to Beckman Coulter is an exciting step for our plans to develop a full portfolio of CDS solutions," Julie Sawyer Montgomery, president of Beckman Coulter Diagnostics told the press. "StoCastic's unique clinical and artificial intelligence expertise is a strong complement to our existing team. Our investment in CDS is a great example of Beckman Coulter relentlessly reimagining healthcare to further improve patient care."
The TriageGo tool integrates with electronic health record (EHR) systems and routine emergency department workflow. TriageGo has been shown to reduce decision making times in the emergency department (ED), shrinking door-to-clinical decision time by 20-30 minutes, door-to-ICU times by 40-80 minutes, and door-to-ED departure for those undergoing emergency surgeries by 30-60 minutes.
"We are thrilled to be joining Beckman Coulter Diagnostics," said Eric Hamrock, Senior Director, CDS Service, Beckman Coulter Diagnostics and former CEO, StoCastic LLC. "Beckman Coulter will bring world-class market understanding and customer experience leadership, in addition to their commitment to supporting and building upon StoCastic's customers' success, making this a perfect fit for our organization."
"With the StoCastic acquisition, we combine Beckman Coulter Diagnostics biomarkers with TriageGo's evidence-based CDS to generate advanced decision support insights. This will enable clinicians to make informed decisions sooner and further improve patient outcomes," added Kelly Sager, VP and GM, CDS Solutions at Beckman Coulter Diagnostics.
TriageGo was developed by researchers at Johns Hopkins Medicine.
StoCastic’s TriageGo toll will become a cornerstone of Beckman Coulter’s AI-enabled Clinical Decision Support (CDS) portfolio, which aims to improve patient care through data-driven insights for clinicians and boost decision making.
"Bringing in StoCastic innovations and talent to Beckman Coulter is an exciting step for our plans to develop a full portfolio of CDS solutions," Julie Sawyer Montgomery, president of Beckman Coulter Diagnostics told the press. "StoCastic's unique clinical and artificial intelligence expertise is a strong complement to our existing team. Our investment in CDS is a great example of Beckman Coulter relentlessly reimagining healthcare to further improve patient care."
The TriageGo tool integrates with electronic health record (EHR) systems and routine emergency department workflow. TriageGo has been shown to reduce decision making times in the emergency department (ED), shrinking door-to-clinical decision time by 20-30 minutes, door-to-ICU times by 40-80 minutes, and door-to-ED departure for those undergoing emergency surgeries by 30-60 minutes.
"We are thrilled to be joining Beckman Coulter Diagnostics," said Eric Hamrock, Senior Director, CDS Service, Beckman Coulter Diagnostics and former CEO, StoCastic LLC. "Beckman Coulter will bring world-class market understanding and customer experience leadership, in addition to their commitment to supporting and building upon StoCastic's customers' success, making this a perfect fit for our organization."
"With the StoCastic acquisition, we combine Beckman Coulter Diagnostics biomarkers with TriageGo's evidence-based CDS to generate advanced decision support insights. This will enable clinicians to make informed decisions sooner and further improve patient outcomes," added Kelly Sager, VP and GM, CDS Solutions at Beckman Coulter Diagnostics.
TriageGo was developed by researchers at Johns Hopkins Medicine.